Overlerde Anjiyogenezi Etkileyen Faktörler

Yıl 2017, Cilt: 26 Sayı: 3, 330 - 341, 30.09.2017

Latife Seyran Çelik Ufuk Özgü Mete

https://doi.org/10.17827/aktd.303589

Öz

Daha önce oluşan kan damarlarından filizlenme yoluyla yeni kan damarlarının oluşum süreci olan anjiyogenez, vücudumuzda hem fizyolojik hem de patolojik birçok durumda görülmektedir. Overlerde anjiyogenez, ovaryan siklusun foliküler ve luteal fazları sırasında normal ovaryan fizyolojik aktivasyonda ve çeşitli ovaryan hastalıklar ile neoplazilerde önemli rol oynamaktadır. Overlerde normal fonksiyon, anjiyogenezi etkileyen birçok proanjiyogenik ve antianjiyogenik faktörler aracılığıyla gerçekleşir. Bu faktörlerin en önemlileri vasküler endotelyal büyüme faktörü, fibroblast büyüme faktörü, anjiyotensin II ve matriks metalloproteinazlar olmakla birlikte, diğer birçok faktör de bu süreçte yer almaktadır. Günümüzde bu konuda artan bilgi birikimi birçok hastalığın patogenezinin anlaşılmasına ve tedavisinde yeni terapötik yaklaşımların ortaya çıkmasına olanak sağlayacaktır.

Anahtar Kelimeler

anjiyogenezis, anjiyogenez inhibitörleri, over

Factors Affecting Angiogenesis in Ovaries

Öz

Angiogenesis is the process of new capillary formation from preexisting vessels that occurs in both the physiological and pathological processes in our body. Ovarian angiogenesis participates in normal ovarian physiologic activation, various ovarian diseases and neoplasms throughout the follicular and luteal phases of the ovarian cycle. The normal ovarian function modulated by a wide range of proangiogenic and antiangiogenic factors that directly affects angiogenesis. The most important of these factors are vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor, angiotensin ıı, matrix metalloproteinases as well as many other factors are involved in this process. Today increased knowledge in this issues will enable the emergence of new therapeutic approaches in the understanding and treatment of pathogenesis of many diseases.

Anahtar Kelimeler

angiogenesis, angiogenesis inhibitors, ovary

Kaynakça

• 1. Ross MH, Pawlina W. Histology: A text and atlas. 6th ED, Philadelphia: Lippincott Williams & Wilkins 2011.
• 2. Telfer EE. The development of methods for isolation and culture of preantral follicles from bovine and porcine ovaries. Theriogenology 1996; 45: 101-110.
• 3. Hulshof SCJ, Figueiredo JR, Bekers JF, Bevers MM, Van Den Hurk R. Isolation and Characterization of preantral follicles from foetal bovine ovaries. Vet Q. 1994; 2: 78-80.
• 4. Bruno JB, Matos MHT, Chaves RN, Celestino JJH, Saraiva MVA, Lima-Verde IB et al. Angiogenic factors and ovarian follicle development. Anim. Reprod. Sci. 2009; 6(2):371-379.
• 5. Berisha B, Schams D, Rodler D, Pfaffl MW. Angiogenesis in The Ovary - The Most Important Regulatory Event for Follicle and Corpus Luteum Development and Function in Cow - An Overview. Anat Histol Embryol. 2016; 45(2):124-30.
• 6. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671–4.
• 7. Redmer DA, Doraiswamy V, Bortnem BJ, Fisher K, Jablonka-Shariff A, Grazul-Bilska AT et al. Evidence for a role of capillary pericytes in vascular growth of the developing ovine corpus luteum. Biol Reprod. 2001; 65: 879-889.
• 8. Abulafia o, Sherer DM. Angiogenesis of the ovary. Am J Obstet Gynecol. 2000; 182: 240-6.
• 9. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9(2): 267-.
• 10. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol. 2002; 55: 348-359.
• 11. Liekens S, De Clercq E, Neyts J. Angiogenesis: Regulators and clinical applications. Biochem Pharmacol. 2001; 61: 253–7.
• 12. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest. 1999; 103: 1237–41.
• 13. Kalluri R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nature Reviews Cancer 2003; 3: 422–33.
• 14. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews Cancer, 2002; 2: 727–39.
• 15. Martelli A, Bernabò N, Berardinelli P, Russo V, Rinaldi C, Di Giacinto O et al. Vascular supply as a discriminating for pig preantral follicle selection. Reproduction 2009; 137: 45-58.
• 16. Stouffer RL, Martínez-Chequer JC, Molskness TA, Xu F, Hazzard TM. Regulation and action of angiogenic factors in the primate ovary. Arch Med Res 2001, 32: 567-575.
• 17. Jiang JY, Macchiarelli G, Tsang BK, Sato E. Capillary angiogenesis and degeneration in bovine ovarian antral follicles. Reproduction 2003; 125: 211-223.
• 18. Tamanini C, De Ambrogi M. Angiogenesis in developing follicle and corpus luteum. Reprod Dom Anim. 2004; 39: 206-216.
• 19. Plendl J. Angiogenesis and vascular regression in the ovary. Anat Histol Embryol. 2000; 29: 257-266.
• 20. Doraiswamy V, Knutson DL, Grazul-Bilska AT, Redmer DA, Reynolds LP. Fibroblast growth factor receptor (FGFR)-1 and -2 in the ovine corpus luteum throughout the estrous cycle. Growth Factors 1998; 16(2): 125-35.
• 21. Hazzard TM, Stouffer RL. Angiogenesis in ovarian follicular and luteal development. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000; 4: 883-900.
• 22. Espinosa-Cervantes MC, Rosado-Garcia A. Angiogenesis in reproductive physiology: follicular development, formation and maintenance of the corpus luteum. Ginecol Obstet Mex. 2002; 70: 17-27.
• 23. Petrik JJ, Gentry PA, Feige JJ, Lamarre J. Expression and localization of thrombospondin-1 and -2 and their cell surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol Reprod, 2002; 67:1522-1531.
• 24. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature, 2000; 407: 249–57.
• 25. Demirer E, Ayten Ö, Taş D. Angiogenesis and Anti-Angiogenic Treatments. J Clin Anal Med. 2014; 5(1): 75-79.
• 26. Ruoslahti E. Specialization of tumor vasculature. Nature Reviews Cancer 2002; 2: 83–90.
• 27. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39(13): 1948-56.
• 28. Goldman S., Shalev E. The role of the matrix metalloproteinases in human endometrial and ovarian cycles. Eur J Obstet Gynecol Reprod Biol. 2003; 111: 109–121.
• 29. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution. Biochim Biophys Acta. 2000; 1477: 267–83.
• 30. Robinson LL, Sznajder NA, Riley SC, Anderson RA. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human fetal testis and ovary. Mol Hum Reprod. 2001; 7: 641–8.
• 31. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res., 2001; 7(1): 14-23.
• 32. Abdelazim IA, Abu faza ML, Al-Kadi M. Immunoexpression of matrix metalloproteinase–2 (MMP–2) in epithelial ovarian cancers (EOCs). Asian Pacific Journal of Reproduction 2013; 2(2): 136-141.
• 33. Kamel H, Abdelazim I, Habib SM, El Shourbagy MA, Ahmed NS. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J Obstet Gynaecol Can. 2010; 32(6):580-6.
• 34. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R.The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol. 2002; 22;187(1-2): 39-45.